Experimental CRISPR Phage Therapy Shows Clinical Response in Multidrug-Resistant Infection

An experimental CRISPR-armed phage therapy, SNIPR001, has demonstrated a notable clinical response in a kidney transplant patient suffering from recurrent multidrug-resistant E. coli infections. This expanded-access case suggests the therapy's potential for treating established infections beyond the gut. Further controlled clinical trials are necessary to confirm these initial findings.